학술논문
Methods to evaluate the impact of SARS-CoV-2 nucleocapsid mutations on antigen detection by rapid diagnostic tests
Document Type
Article
Author
Tieman, Bryan C; Kovacs, Stephen; Rodgers, Mary A; Mohaimani, Aurash; Gregory, Svetoslava; Christensen, David; Moore, Jeffrey A; Schurig-Briccio, Lici; Hartnett, James; Kar, Alak; Leeman, Aaron; Palmer, Angel; Rogers, Lauren; Dragoo, Brian; Muszynski, Steven; Noblesmith, Deborah; Gardner, Samantha; Snipe-Bushey, Abigail; Kill, Anna; Luo, Xinxin; Cherukuri, Sneha; Rae, Tracey; Marohnic, Christopher C; Cloherty, Gavin A; Muerhoff, Anthony Scott; Hemken, Philip M
Source
Biotechniques; August 2022, Vol. 73 Issue: 3 p136-141, 6p
Subject
Language
ISSN
07366205
Abstract
Mutations in the nucleocapsid of SARS-CoV-2 may interfere with antigen detection by diagnostic tests. We used several methods to evaluate the effect of various SARS-CoV-2 nucleocapsid mutations on the performance of the Panbio™ and BinaxNOW™ lateral flow rapid antigen tests and a prototype high-throughput immunoassay that utilizes Panbio antibodies. Variant detection was also evaluated by immunoblot and BIAcore™ assay. A panel of 23 recombinant nucleocapsid antigens (rAgs) were produced that included mutations found in circulating SARS-CoV-2 variants, including variants of concern. All mutant rAgs were detected by all assays, at a sensitivity equivalent to wild-type control (Wuhan strain). Thus, using a rAg approach, we found that the SARS-CoV-2 nucleocapsid mutations examined do not directly impact antigen detection or antigen assay performance.